NO952912L - En ny osteoblastisk proliferativ faktor - Google Patents

En ny osteoblastisk proliferativ faktor

Info

Publication number
NO952912L
NO952912L NO952912A NO952912A NO952912L NO 952912 L NO952912 L NO 952912L NO 952912 A NO952912 A NO 952912A NO 952912 A NO952912 A NO 952912A NO 952912 L NO952912 L NO 952912L
Authority
NO
Norway
Prior art keywords
new
proliferative factor
osteoblastic
bone
diseaese
Prior art date
Application number
NO952912A
Other languages
English (en)
Norwegian (no)
Other versions
NO952912D0 (no
Inventor
Akira Kudo
Tohru Nakanishi
Masaharu Takigawa
Original Assignee
Hoechst Japan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Japan filed Critical Hoechst Japan
Publication of NO952912D0 publication Critical patent/NO952912D0/no
Publication of NO952912L publication Critical patent/NO952912L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
NO952912A 1994-07-22 1995-07-21 En ny osteoblastisk proliferativ faktor NO952912L (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP20125794A JP3738281B2 (ja) 1994-07-22 1994-07-22 新規な骨芽細胞増殖因子

Publications (2)

Publication Number Publication Date
NO952912D0 NO952912D0 (no) 1995-07-21
NO952912L true NO952912L (no) 1996-01-23

Family

ID=16437950

Family Applications (1)

Application Number Title Priority Date Filing Date
NO952912A NO952912L (no) 1994-07-22 1995-07-21 En ny osteoblastisk proliferativ faktor

Country Status (14)

Country Link
US (1) US6080720A (de)
EP (1) EP0704219B1 (de)
JP (1) JP3738281B2 (de)
KR (1) KR100361717B1 (de)
AT (1) ATE206930T1 (de)
AU (1) AU693567B2 (de)
CA (1) CA2154403A1 (de)
DE (1) DE69523250T2 (de)
DK (1) DK0704219T3 (de)
ES (1) ES2161809T3 (de)
FI (1) FI953514A7 (de)
HU (1) HU217082B (de)
NO (1) NO952912L (de)
PT (1) PT704219E (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2523672B1 (de) * 2010-01-15 2016-07-13 Rutgers, the State University of New Jersey Verwendung von vanadiumverbindungen für beschleunigte knochenheilung
CN103781358A (zh) 2010-12-10 2014-05-07 新泽西医科和牙科大学 涂布有胰岛素模拟剂复合材料的可植入装置及其方法
US20140322292A1 (en) 2010-12-10 2014-10-30 Rutgers, The State University Of New Jersey Insulin-mimetics as therapeutic adjuncts for bone regeneration
US9931348B2 (en) 2011-07-06 2018-04-03 Rutgers, The State University Of New Jersey Vanadium compounds as therapeutic adjuncts for cartilage injury and repair

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL95511A (en) * 1989-08-30 2000-10-31 Max Planck Gesellschaft Neurotrophin-3 a novel neurotrophic factor related to nerve growth and brain derived neurotrophic factor
AU2460595A (en) * 1994-05-06 1995-11-29 Regeneron Pharmaceuticals, Inc. Methods based on the role of neurotrophin 3 in female reproduction

Also Published As

Publication number Publication date
EP0704219A3 (de) 1997-12-10
DE69523250T2 (de) 2002-07-04
HU217082B (hu) 1999-11-29
PT704219E (pt) 2002-03-28
CA2154403A1 (en) 1996-01-23
FI953514L (fi) 1996-01-23
ATE206930T1 (de) 2001-11-15
US6080720A (en) 2000-06-27
ES2161809T3 (es) 2001-12-16
EP0704219B1 (de) 2001-10-17
FI953514A0 (fi) 1995-07-20
EP0704219A2 (de) 1996-04-03
AU2710595A (en) 1996-02-01
HUT73185A (en) 1996-06-28
DK0704219T3 (da) 2002-02-04
DE69523250D1 (de) 2001-11-22
AU693567B2 (en) 1998-07-02
JP3738281B2 (ja) 2006-01-25
KR960003741A (ko) 1996-02-23
HU9502202D0 (en) 1995-09-28
NO952912D0 (no) 1995-07-21
JPH0834744A (ja) 1996-02-06
KR100361717B1 (ko) 2003-07-07
FI953514A7 (fi) 1996-01-23

Similar Documents

Publication Publication Date Title
DE69825292D1 (de) Verwendung von inosine zur herstellung eines medikamentes zur stimulierung des axonwachstums von zns-neuronen
RU94027680A (ru) Паращитовидный гормон и ралоксифон для увеличения массы кости, фармацевтический состав и способ увеличения костной массы
UA29505C2 (uk) Фармацевтична композиція для лікування і/або профілактики розрідження кістки і спосіб лікування і/або профілактики розрідження кістки у ссавців
DE4497905T1 (de) Pharmazeutische Zusammensetzung zur Prävention und Behandlung des Motion-Sickness-Syndroms
ES2173111T3 (es) Uso de fenserina para la preparacion de medicamentos para el tratamiento de desordenes cognoscitivos.
IL114683A0 (en) Combination treatment for inhibiting bone loss
ATE238799T1 (de) Verfahren und mittel zur arzneistoffverabreichung
DE69332732D1 (de) Pharmazeutische Zusammensetzung und Methode zur Behandlung von Hyperlipidämie und Arterioskerose
BR9813318A (pt) Processo de tratamento de tumores e degeneração macular em paciente humano ou veterinário, composição farmacêutica para tratamento de tumores e degeneração macular em um paciente humano ou veterinário
DE69420776D1 (de) Idebenone-haltige Zusammensetzungen zur Behandlung von M. Alzheimer
FI962685A7 (fi) 2,3-diaryyli-1-bentsopyraanijohdannaisten käyttö lääkkeen valmistamise ksi luukadon ja osteoporoosin hoitamiseksi ja estämiseksi
BR9809678A (pt) Derivados de triptolìdeo úteis no tratamento de doenças autoimunes
DE69420229D1 (de) Pharmazeutische Zusammensetzung zur Behandlung von AIDS
DE69426530D1 (de) Pharmazeutische zusammensetzung zur förderung der gewebeheilung und -regenerierung und darreichungssatz
NO952912D0 (no) En ny osteoblastisk proliferativ faktor
EP0744176A3 (de) Arzneimittel zur Hemmung von Knochenschwund
RU94041028A (ru) Применение производных мелатонина для лечения десинхронизационных нарушений, фармацевтическая композиция
DE69100171D1 (de) Synergistische kombination zur ophthalmischen verwendung.
NO984196L (no) FremgangsmÕte for behandling av stoffmisbruk
NO20010984D0 (no) Anvendelse av R(+)-<alfa>-(2,3-dimetoksyfenyl)-1-[2-(4- fluorfenyl)etyl]-4-piperidinmetanol for behandling av søvnforstyrrelser
IT1276706B1 (it) Bicarbonati di derivati della 2,6-dimetilanilina, loro uso in terapia e composizioni farmaceutiche che li comprendono
IL103499A0 (en) Pharmaceutical compositions for treating anxiety in benzodiazepine withdrawn patients
NO974941L (no) Ny anvendelse av (S)-adenosyl-L-metionin(SAMe)
SG64899A1 (en) Method and composition for treatment of patients having decompsated liver disease
IT1262567B (it) Pirrolidin-2-oni,loro preparazione,composizioni farmaceutiche che li contengono e loro uso in terapia.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application